Organisation paid for research Program year 2021 Source: CMS Open Payments

Central Dermatology, P.C.

Neither a doctor nor a teaching hospital

Research payments

$435,444

60 payments

Through program year 2021, Central Dermatology, P.C. is reported as receiving $435,444 in research payments, across 60 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $33,441 12
2020 Research $137,085 9
2019 Research $264,918 39

Breakdown

Who paid Research payments · program years 2019–2021
  1. Ucb SA $297,750 27 payments
  2. AbbVie, Inc. $137,474 32 payments
  3. UCB Biosciences Inc. $221 1 payment
Studies the money was for Research payments · program years 2019–2021
  1. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $112,816 2 payments
  2. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoria $72,034 4 payments
  3. M16-766 $66,822 12 payments
  4. M15-997 $62,985 18 payments
  5. A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety of bimekizumab in adult subjects with moderate to $45,046 1 payment
  6. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $26,954 6 payments
  7. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $26,493 10 payments
  8. A Phase 3 Multicenter, randomized, double-blind, placebo - and active comparator-controlled, parallel group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis $12,739 3 payments
  9. M16-005 $7,667 2 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed By A Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis $1,668 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record